Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795312 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29615250 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL13470198 | 0.88 | MDM4 (0.52) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL13470493 | 0.86 | MDM4 (0.50) | MDM4TP53MDM2CASP3 | |
| SCHEMBL12040111 | 0.85 | MDM4 (0.52) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL119483 | 0.85 | MDM4 (0.52) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL5717685 | 0.82 | MDM4 (0.49) | MDM4TP53MDM2CASP3 | |
| SCHEMBL119712 | 0.82 | MDM4 (0.49) | MDM4TP53MDM2CASP3 | |
| SCHEMBL30196497 | 0.82 | MDM4 (0.49) | MDM4TP53MDM2CASP3 | |
| SCHEMBL31369795 | 0.82 | MDM4 (0.53) | MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11753444-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20210079043-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | Bicyclerd Limited (GB) | 2021-03-18 | — | — | US | disclosed |
| US-10870679-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-2983722-B1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | BICYCLERD LTD (GB) | 2018-12-12 | — | — | EP | disclosed |
| US-10118947-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2018-11-06 | — | — | US | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| US-20160046673-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | BICYCLE THERAPEUTICS LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2983722-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | Bicycle Therapeutics Limited (GB) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014167122-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | BICYCLE THERAPEUTICS LIMITED (GB) | 2014-10-16 | — | — | WO | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | MDM4 3675/4885TP53 4241/4885MDM2 4184/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885MDM2 4288/4885 |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | MDM4 1071/4885TP53 452/4885MDM2 1062/4885 |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | SERPINC1, TEK, ARGLU1 | MDM4 3675/4885TP53 4241/4885MDM2 4184/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885MDM2 4288/4885 |
| US-10870679-B2 | Modulation of structured polypeptide specificity | KLKB1, KLK5, KLK1 | MDM4 3079/4885TP53 3247/4885MDM2 4091/4885 |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885MDM2 4288/4885 |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885MDM2 4288/4885 |
| US-10118947-B2 | Modulation of structured polypeptide specificity | KLKB1, KLK5, KLK1 | MDM4 3079/4885TP53 3247/4885MDM2 4091/4885 |
| US-11753444-B2 | Modulation of structured polypeptide specificity | KLKB1, KLK5, KLK1 | MDM4 3079/4885TP53 3247/4885MDM2 4091/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885MDM2 4288/4885 |
| US-20210079043-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | KLKB1, KLK5, KLK1 | MDM4 3079/4885TP53 3247/4885MDM2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.